NCT03769181 2025-09-23
A Study of Isatuximab-based Therapy in Participants With Lymphoma
Sanofi
Phase 1/2 Terminated
Clinical Trials
8 trialsNCT06119685 2025-06-03
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Indapta Therapeutics, INC.
Phase 1/2 Recruiting
NCT03989414 2024-11-29
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
Celgene
Phase 1/2 Active not recruiting
NCT03194867 2024-06-14
Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients
Sanofi
Phase 1/2 Completed
NCT02812706 2024-04-01
Islands
Sanofi
Phase 1/2 Completed
NCT03555149 2023-11-07
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)
Hoffmann-La Roche
Phase 1/2 Terminated
NCT03637764 2023-07-10
Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies
Sanofi
Phase 1/2 Terminated
NCT03367819 2022-05-16
Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies
Sanofi
Phase 1/2 Terminated